A clinical study for Levosimendan improvement of prognosis of ARDS patients by optimizing pulmonary hemodynamics

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024129

Enrollment

Unknown

Registered

2019-06-26

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Interventions

experimental group :Levosimendan combined with conventional therapy

control group:conventional therapy

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: All patients admitted to ICU diagnosed as ARDS according to 2012 Berlin criteria were included in the study if informed consent met the ethical requirements of the hospital

Exclusion criteria

Exclusion criteria: Patients who were definited with nerves and muscle diseases that could not escape; those with chronic severe liver and kidney failure; those with advanced malignant tumors; those with primary ARDS that could not be removed or effectively controlled; those with primary left ventricular insufficiency; and those who died or were discharged automatically from the left heart during the study and observation period.

Design outcomes

Primary

Measure	Time frame
APACHE II score;Cardiac function index;	—

Secondary

Measure	Time frame
SOFA score;	—

Countries

China

Contacts

Public ContactMeng Xinke

Shenzhen Second People's Hospital

mengxinke_126@126.com+86 13751017051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026